The Delta Variant: Current Evidence and Literature - COVID-19 | SARS-CoV-2 | Vaccine Efficacy

Ninja Nerds!

In this lecture Professor Zach Murphy will be presenting on The Delta Variant: Current Evidence and Literature - COVID-19 | SARS-CoV-2 | Vaccine Efficacy- as of August 16, 2021.

During this lecture we will be providing you with the most up to date evidence and literature discussing the Delta Variant and current state of the COVID-19 pandemic. We will begin this lecture by referring to the whiteboard on the current variants of concern and their pathophysiology. Next, we will take a look at current research supporting variants of concern and their relevant attributes. We will then be discussing the research defining the viral load of the Delta variant, and will then support this with evidence from a variety of reputable sources including UpToDate and the CDC. The next chapter of this lecture is a brief discussion on the overall transmissibility of the Delta variant. We look at the transmissibility or the spreadability of this Delta variant in comparison to ancestral strains and the Alpha variant. We will support these findings with current evidence on transmissibility from Public Health England and the CDC. Following this discussion, we move into the severity of the Delta variant in comparison to ancestral strains and the Alpha variant. Once again, we utilize the whiteboard and recently published articles to support our findings on the severity of the Delta variant. We will then transition into the prevalence / most affected populations in regard to the Delta variant. We support our lecture through the use of articles / research studies published by Public Health England, CDC, and The New York Times. The next chapter of our lecture is a discussion on the symptoms and treatment of COVID-19, particularly those affected by the Delta variant. We highlight the different symptoms patients are presenting with in comparison to ancestral strains and the Alpha variant. Finally, we conclude this lecture with a very important discussion on vaccine efficacy, and the potential risk of reinfection rates in regard to the Delta variant.